1. Accumulating breast cancer stem cell populations through IL-6 and IL-8 signaling pathways2. Increasing expression of multidrug resistance 13. Down-regulation of chemotherapeutic drug targets by HIF-1. Here, IL6 is linked to breast carcinoma.